Pall acquires MicroReactor Technologies

The acquisition of MRT, with its miniature bioreactor technology platform, expands Pall’s Total Fluid Management capabilities in the biopharmaceuticals process monitoring and process development market.

“We are excited by this acquisition and the increased opportunities it presents for our biotechnology process development and laboratory programs,” said Eric Krasnoff, Pall chairman and CEO. “Customers seek better tools for rapid process development and process monitoring. The addition of MRT further broadens Pall Life Sciences support of customers in this rapidly growing market. We welcome the newest members of the Pall family.”

“It is exciting to join Pall and support the rapid growth in our business. More importantly, it enables our customers to exploit on a wider scale, the very significant advantages that the Micro-24 bioreactor technology is bringing to the industry,” said Stephen Boyer, president of MRT.